Current Hypertension Reports

, Volume 8, Issue 1, pp 54–59

Endothelial arginase: A new target in atherosclerosis



Decreased endothelial nitric oxide (NO) bioavailability as it relates to endothelial dysfunction plays an important role in various cardiovascular disorders, including atherosclerosis. Recent research has provided evidence that endothelial dysfunction in atherosclerosis is not primarily caused by decreased endothelial NO synthase (eNOS) gene expression, but rather deregulation of eNOS enzymatic activity, which contributes to the increased oxidative stress in atherosclerosis. Among other mechanisms, the substrate L-arginine is an important limiting factor for NO production. Emerging evidence demonstrates that L-arginine is not only converted to NO via eNOS, but also metabolized to urea and L-ornithine via arginase in endothelial cells. Hence, arginase competes with eNOS for the substrate L-arginine, resulting in deceased NO production. There are an increasing number of studies showing that enhanced arginase gene expression and/or activity contribute to endothelial dysfunction in various cardiovascular disorders, including atherosclerosis. Thus, endothelial arginase may represent a new therapeutic target in atherosclerosis.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005, 111:3481–3488.PubMedCrossRefGoogle Scholar
  2. 2.
    Halcox JP, Schenke WH, Zalos G, et al.: Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002, 106:653–658.PubMedCrossRefGoogle Scholar
  3. 3.
    Bugiardini R, Manfrini O, Pizzi C, et al.: Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 2004, 109:2518–2523.PubMedCrossRefGoogle Scholar
  4. 4.
    Yang Z, Luscher TF: Vascular endothelium. In PanVascularMedicine. Edited by Lanzer P, Topol EJ. Berlin-Heidelberg-New York: Springer; 2002:190–204.Google Scholar
  5. 5.
    Knowles JW, Reddick RL, Jennette JC, et al.: Enhanced atherosclerosis and kidney dysfunction in eNOS (-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 2000, 105:451–458.PubMedGoogle Scholar
  6. 6.
    Kauser K, da Cunha V, Fitch R, et al.: Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Physiol Heart Circ Physiol 2000, 278:H1679-H1685.PubMedGoogle Scholar
  7. 7.
    Sessa WC: eNOS at a glance. J Cell Sci 2004, 117:2427–2429.PubMedCrossRefGoogle Scholar
  8. 8.
    Oemar BS, Tschudi MR, Godoy N, et al.: Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998, 97:2494–2498.PubMedGoogle Scholar
  9. 9.
    Davignon J, Ganz P: Role of endothelial dysfunctionin atherosclerosis. Circulation 2004, 109(23 Suppl 1): III27-III32.PubMedGoogle Scholar
  10. 10.
    Matsumoto T, d’Uscio LV, Eguchi D, et al.: Protective effect of chronic vitamin C treatment on endothelial function of apolipoprotein E-deficient mouse carotid artery. J Pharmacol Exp Ther 2003, 306:103–108.PubMedCrossRefGoogle Scholar
  11. 11.
    Godecke A, Ziegler M, Ding Z, et al.: Endothelial dysfunction of coronary resistance vessels in apoE-/-mice involves NO but not prostacyclin-dependent mechanisms. Cardiovasc Res 2002, 53:253–262.PubMedCrossRefGoogle Scholar
  12. 12.
    d’Uscio LV, Baker TA, Mantilla CB, et al.: Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:1017–1022.PubMedGoogle Scholar
  13. 13.
    Ming XF, Barandier C, Viswambharan H, et al.: Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 2004, 110:3708–3714. This is the first study showing that endothelial arginase activity is regulated by the Rho/ROCK pathway. Arginase activity is increased in atherosclerotic aortas in ApoE-/-mice and plays a substantial role in endothelial dysfunction in atherosclerosis.PubMedCrossRefGoogle Scholar
  14. 14.
    Wilcox JN, Subramanian RR, Sundell CL, et al.: Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997, 17:2479–2488.PubMedGoogle Scholar
  15. 15.
    Fukuchi M, Giaid A: Endothelial expression of endothelial nitric oxide synthase and endothelin-1 in human coronary artery disease. Specific reference to underlying lesion. Lab Invest 1999, 79:659–670.PubMedGoogle Scholar
  16. 16.
    Rossi ML, Marziliano N, Merlini PA, et al.: Phenotype commitment in vascular smooth muscle cells derived from coronary atherosclerotic plaques: differential gene expression of endothelial nitric oxide synthase. Eur J Histochem 2005, 49:39–46.PubMedGoogle Scholar
  17. 17.
    Ozaki M, Kawashima S, Yamashita T, et al.: Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 2002, 110:331–340.PubMedCrossRefGoogle Scholar
  18. 18.
    van HaperenR, de WaardM, van DeelE, et al.: Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. J Biol Chem 2002, 277:48803–48807.PubMedCrossRefGoogle Scholar
  19. 19.
    Munzel T, Daiber A, Ullrich V, et al.: Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 2005, 25:1551–1557.PubMedCrossRefGoogle Scholar
  20. 20.
    Drexler H, Zeiher AM, Meinzer K, et al.: Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991, 338:1546–1550.PubMedCrossRefGoogle Scholar
  21. 21.
    Cooke JP, Singer AH, Tsao P, et al.: Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992, 90:1168–1172.PubMedCrossRefGoogle Scholar
  22. 22.
    Creager MA, Gallagher SJ, Girerd XJ, et al.: L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992, 90:1248–1253.PubMedGoogle Scholar
  23. 23.
    Dubois-Rande JL, Zelinsky R, Roudot F, et al.: Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Am J Cardiol 1992, 70:1269–1275.PubMedCrossRefGoogle Scholar
  24. 24.
    Loscalzo J: Adverse effects of supplemental L-arginine in atherosclerosis: consequences of methylation stress in a complex catabolism? Arterioscler Thromb Vasc Biol 2003, 23:3–5. A critical editorial comment analyzing controversial results with L-arginine supplemental therapy obtained from experimental and clinical studies.PubMedCrossRefGoogle Scholar
  25. 25.
    Jeremy RW, McCarron H, Sullivan D: Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilatation in the hypercholesterolemic rabbit. Response according to treatment duration, anatomic site, and sex. Circulation 1996, 94:498–506.PubMedGoogle Scholar
  26. 26.
    Oomen CM, van Erk MJ, Feskens EJ, et al.: Arginine intake and risk of coronary heart disease mortality in elderly men. Arterioscler Thromb Vasc Biol 2000, 20:2134–2139.PubMedGoogle Scholar
  27. 27.
    Blum A, Hathaway L, Mincemoyer R, et al.: Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000, 101:2160–2164.PubMedGoogle Scholar
  28. 28.
    Walker HA, McGing E, Fisher I, et al.: Endotheliumdependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001, 38:499–505.PubMedCrossRefGoogle Scholar
  29. 29.
    Wennmalm A, Edlund A, Granstrom EF, et al.: Acute supplementation with the nitric oxide precursor L-arginine does not improve cardiovascular performance in patients with hypercholesterolemia. Atherosclerosis 1995, 118:223–231.PubMedCrossRefGoogle Scholar
  30. 30.
    Miller HI, Dascalu A, Rassin TA, et al.: Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial. Am J Nephrol 2003, 23:91–95.PubMedCrossRefGoogle Scholar
  31. 31.
    Chen J, Kuhlencordt P, Urano F, et al.: Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase doubleknockout mice. Arterioscler Thromb Vasc Biol 2003, 23:97–103.PubMedCrossRefGoogle Scholar
  32. 32.
    Simonet S, Rupin A, Badier-Commander C, et al.: Evidence for superoxide anion generation in aortas of cholesterolfed rabbits treated with L-arginine. Eur J Pharmacol 2004, 492:211–216.PubMedCrossRefGoogle Scholar
  33. 33.
    Wu G, Morris SMJr: Arginine metabolism: nitric oxide and beyond. Biochem J 1998, 336:1–17.PubMedGoogle Scholar
  34. 34.
    Durante W, Liao L, Reyna SV, et al.: Transforming growth factor-beta(1) stimulates L-arginine transport and metabolism in vascular smooth muscle cells: role in polyamine and collagen synthesis. Circulation 2001, 103:1121–1127.PubMedGoogle Scholar
  35. 35.
    Morris SMJr, Bhamidipati D, Kepka-Lenhart D: Human type II arginase: sequence analysis and tissue-specific expression. Gene 1997, 193:157–161.PubMedCrossRefGoogle Scholar
  36. 36.
    Cederbaum SD, Yu H, Grody WW, et al.: Arginases I and II: Do their functions overlap? Mol Genet Metab 2004, 81(Suppl 1):S38-S44.PubMedCrossRefGoogle Scholar
  37. 37.
    Zhang C, Hein TW, Wang W, et al.: Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 2001, 15:1264–1266.PubMedCrossRefGoogle Scholar
  38. 38.
    Buga GM, Singh R, Pervin S, et al.: Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol 1996, 271:H1988-H1998.PubMedGoogle Scholar
  39. 39.
    Bachetti T, Comini L, Francolini G, et al.: Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 2004, 37:515–523.PubMedCrossRefGoogle Scholar
  40. 40.
    Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, et al.: Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun 2001, 283:923–927.PubMedCrossRefGoogle Scholar
  41. 41.
    Cama E, Colleluori DM, Emig FA, et al.: Human arginase II: crystal structure and physiological role in male and female sexual arousal. Biochemistry 2003, 42:8445–8451.PubMedCrossRefGoogle Scholar
  42. 42.
    Berkowitz DE, White R, Li D, et al.: Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003, 108:2000–2006.PubMedCrossRefGoogle Scholar
  43. 43.
    Sakai Y, Masuda H, Kihara K, et al.: Involvement of increased arginase activity in impaired cavernous relaxation with aging in the rabbit. J Urol 2004, 172:369–373.PubMedCrossRefGoogle Scholar
  44. 44.
    Hein TW, Zhang C, Wang W, et al.: Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 2003, 17:2328–2330.PubMedGoogle Scholar
  45. 45.
    Zhang C, Hein TW, Wang W, et al.: Upregulation of vascular arginase in hypertension decreases nitric oxidemediated dilation of coronary arterioles. Hypertension 2004, 44:935–943.PubMedCrossRefGoogle Scholar
  46. 46.
    Johnson FK, Johnson RA, Peyton KJ, et al.: Arginase inhibitionrestores arteriolar endothelial function in Dahl ratswith salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2004, Dec 9, [Epub ahead of print].Google Scholar
  47. 47.
    Demougeot C, Prigent-Tessier A, Marie C, et al.: Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 2005, 23:971–978. An important study demonstrating that arginase expression and activity are increased in spontaneous hypertensive rats, and treatment of the rat with an arginase inhibitor improves endothelial function and decreases blood pressure in the animals.PubMedCrossRefGoogle Scholar
  48. 48.
    Xu W, Kaneko FT, Zheng S, et al.: Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004, 18:1746–1748.PubMedGoogle Scholar
  49. 49.
    Morris CR, Kato GJ, Poljakovic M, et al.: Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005, 294:81–90. The first clinical study showing that increased arginase activity in plasma and red blood cells is independently associated with pulmonary hypertension and mortality in patients with sickle cell disease.PubMedCrossRefGoogle Scholar
  50. 50.
    Nelin LD, Chicoine LG, Reber KM, et al.: Cytokineinducedendothelial arginase expression is dependent onepidermal growth factor receptor. Am J Respir Cell Mol Biol 2005, Jun 30, [Epub ahead of print].Google Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Vascular Biology, Department of Medicine, Division of PhysiologyUniversity of FribourgFribourgSwitzerland

Personalised recommendations